
17/12/2024
“These approaches have not worked,” George Perry, a neuroscientist at the University of Texas at San Antonio, told BioSpace, referring to Biogen and Eisai’s Aduhelm and Leqembi and Eli Lilly’s Kisunla. “The patients are not getting better.”
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of these anti-amyloid antibodies and the amyloid hypothesis overall.